Efficacy News and Research

RSS

Capsugel launches Coni-Snap sprinkle capsule for people with difficulties swallowing

Capsugel is launching an innovative capsule design to improve adherence to treatment regimens for patients with difficulties swallowing. These patients include babies, children, and older adults as well as patients with medical conditions such as Alzheimer's, Parkinson's, and Multiple Sclerosis. The new Coni-Snap sprinkle capsule is expected to be available in 2014.

22 Oct 2013

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

$Adalimumab may be viable treatment option for patients with refractory pediatric uveitis$

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

A new study published in the current issue of the Journal of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) suggests that the biologic agent adalimumab may be a viable treatment option for patients with steroid-resistant refractory pediatric uveitis.

22 Oct 2013

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Guerbet LLC, USA -- Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).

22 Oct 2013

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.

21 Oct 2013

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).

21 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Anergis, a company focusing on proprietary allergy vaccines, today reported immunology data from the Phase IIb study of its lead compound AllerT.

21 Oct 2013

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Cell Therapeutics, Inc. (CTI) today announced the presentation of findings from a preclinical study of PIXUVRI® (pixantrone) that suggest its mechanism of inducing tumor cell death is novel and distinct from that of anthracyclines such as doxorubicin.

21 Oct 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer Inc. (NYSE:PFE) announced top-line results from two phase 3b, placebo-controlled studies with Lyrica® (pregabalin) Capsules CV in patients with fibromyalgia (FM) and painful diabetic peripheral neuropathy (DPN), respectively.

19 Oct 2013

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

Medivir AB (OMX:MVIR-B) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients.

19 Oct 2013

FEV1 poor mortality predictor in elderly

Research shows that forced expiratory volume in 1 second % predicted is ineffective for predicting mortality in elderly asthma patients.

18 Oct 2013

Ariad Ends Phase III Leukemia Drug Trial

...

18 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

UCB announced today that the U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) for the treatment of adults with active ankylosing spondylitis.

18 Oct 2013

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

The combination of heat, chemotherapeutic drugs and an innovative delivery system based on nanotechnology may significantly improve the treatment of ovarian cancer while reducing side effects from toxic drugs, researchers at Oregon State University report in a new study.

18 Oct 2013

Jain Foundation Steps Up Efforts To Find Cure For Muscular Dystrophy

...

17 Oct 2013

AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

AmpliPhi BioSciences Corporation, the leader in the development of bacteriophage-based antibacterial therapies to treat antibiotic resistant infections, announces it has entered into Collaboration and License Agreements with UK-based University of Leicester to develop a novel bacteriophage therapy targeting Clostridium difficile, a serious gastrointestinal infection for which new treatments are urgently required.

17 Oct 2013

CardioFocus completes HeartLight EAS pivotal trial enrollment for symptomatic paroxysmal AF

CardioFocus, Inc., developer of the HeartLight Endoscopic Ablation System for the treatment of atrial fibrillation, today announced that it has concluded enrollment of its U.S. pivotal trial evaluating the HeartLight system, for the treatment of symptomatic paroxysmal AF.

17 Oct 2013

Efficacy News and Research

Capsugel launches Coni-Snap sprinkle capsule for people with difficulties swallowing

Clinical trials will help to develop treatment and follow-up of COPD patients

Adalimumab may be viable treatment option for patients with refractory pediatric uveitis

Guerbet receives FDA Orphan Drug Designation for Lipiodol Injection

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Cell Therapeutics presents preclinical study results of PIXUVRI at AACR-NCI-EORTC meeting

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Medivir announces data from phase III studies of simeprevir in patients co-infected with HCV genotype-1 and HIV-1

FEV1 poor mortality predictor in elderly

Ariad Ends Phase III Leukemia Drug Trial

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

FDA approves Cimzia for treatment of adults with active ankylosing spondylitis

Combination of heat, doxorubicin drug and nanotech system may improve ovarian cancer treatment

Jain Foundation Steps Up Efforts To Find Cure For Muscular Dystrophy

AmpliPhi, University of Leicester partner to develop novel bacteriophage therapy against C. difficile

CardioFocus completes HeartLight EAS pivotal trial enrollment for symptomatic paroxysmal AF

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News